These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 31893514)

  • 21. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.
    Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Robinson TM; Osmond D; Russell CB; Vettermann C; Agarwal SK; Li M; Wong WY; Laffan M
    Haemophilia; 2024 Mar; 30(2):320-330. PubMed ID: 38317480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
    Madan B; Ozelo MC; Raheja P; Symington E; Quon DV; Leavitt AD; Pipe SW; Lowe G; Kenet G; Reding MT; Mason J; Wang M; von Drygalski A; Klamroth R; Shapiro S; Chambost H; Dunn AL; Oldenburg J; Chou SC; Peyvandi F; Millar CM; Osmond D; Yu H; Dashiell-Aje E; Robinson TM; Mahlangu J
    J Thromb Haemost; 2024 Jul; 22(7):1880-1893. PubMed ID: 38614387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A.
    Greig JA; Smith MK; Nordin JML; Goode T; Chroscinski EA; Buza EL; Schmidt N; Kattenhorn LM; Wadsworth S; Wilson JM
    Hum Gene Ther; 2022 Apr; 33(7-8):421-431. PubMed ID: 34652966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
    Konkle BA; Shapiro AD; Quon DV; Staber JM; Kulkarni R; Ragni MV; Chhabra ES; Poloskey S; Rice K; Katragadda S; Fruebis J; Benson CC
    N Engl J Med; 2020 Sep; 383(11):1018-1027. PubMed ID: 32905674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.
    Long BR; Robinson TM; Day JRS; Yu H; Lau K; Imtiaz U; Patton KS; de Hart G; Henshaw J; Agarwal S; Vettermann C; Zoog SJ; Gupta S
    Mol Ther; 2024 Jul; 32(7):2052-2063. PubMed ID: 38796703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained expression of human factor VIII in mice using a parvovirus-based vector.
    Chao H; Mao L; Bruce AT; Walsh CE
    Blood; 2000 Mar; 95(5):1594-9. PubMed ID: 10688813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
    McIntosh J; Lenting PJ; Rosales C; Lee D; Rabbanian S; Raj D; Patel N; Tuddenham EG; Christophe OD; McVey JH; Waddington S; Nienhuis AW; Gray JT; Fagone P; Mingozzi F; Zhou SZ; High KA; Cancio M; Ng CY; Zhou J; Morton CL; Davidoff AM; Nathwani AC
    Blood; 2013 Apr; 121(17):3335-44. PubMed ID: 23426947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
    Pasi KJ; Laffan M; Rangarajan S; Robinson TM; Mitchell N; Lester W; Symington E; Madan B; Yang X; Kim B; Pierce GF; Wong WY
    Haemophilia; 2021 Nov; 27(6):947-956. PubMed ID: 34378280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
    Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
    Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
    Balagué C; Zhou J; Dai Y; Alemany R; Josephs SF; Andreason G; Hariharan M; Sethi E; Prokopenko E; Jan HY; Lou YC; Hubert-Leslie D; Ruiz L; Zhang WW
    Blood; 2000 Feb; 95(3):820-8. PubMed ID: 10648392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
    Leavitt AD; Konkle BA; Stine KC; Visweshwar N; Harrington TJ; Giermasz A; Arkin S; Fang A; Plonski F; Yver A; Ganne F; Agathon D; Resa MLA; Tseng LJ; Di Russo G; Cockroft BM; Cao L; Rupon J
    Blood; 2024 Feb; 143(9):796-806. PubMed ID: 37871576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
    Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
    N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.
    Fong S; Handyside B; Sihn CR; Liu S; Zhang L; Xie L; Murphy R; Galicia N; Yates B; Minto WC; Vitelli C; Harmon D; Ru Y; Yu GK; Escher C; Vowinckel J; Woloszynek J; Akeefe H; Mahimkar R; Bullens S; Bunting S
    Mol Ther Methods Clin Dev; 2020 Sep; 18():620-630. PubMed ID: 32775496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
    Xu L; Mei M; Ma X; Ponder KP
    J Thromb Haemost; 2007 Sep; 5(9):1805-12. PubMed ID: 17596134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.
    Powell JS; Ragni MV; White GC; Lusher JM; Hillman-Wiseman C; Moon TE; Cole V; Ramanathan-Girish S; Roehl H; Sajjadi N; Jolly DJ; Hurst D
    Blood; 2003 Sep; 102(6):2038-45. PubMed ID: 12763932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
    Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
    Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.